Brief: Inflarx Announces First Patient Enrolled In Phase Iib Trial With Lead Candidate Ifx-1 In Hidradenitis Suppurativa
08/03/2018 14:47
March 8 (Reuters) - Inflarx Nv IFRX.O :
* INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB
TRIAL WITH
LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA
Source text for Eikon: ID:nBw9l5dFGa
Further company coverage: IFRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum